FIGO Stage 5 Does Not Exist in Gynecologic Cancer Staging
There is no FIGO stage 5 (or stage V) in any gynecologic malignancy staging system. The FIGO staging system for all gynecologic cancers—including cervical, endometrial, ovarian, vaginal, and vulvar cancers—uses stages I through IV only.
Understanding FIGO Staging Structure
The FIGO staging system follows a consistent framework across gynecologic malignancies:
- Stage I: Disease confined to the primary organ
- Stage II: Local extension beyond the primary organ but within the pelvis
- Stage III: Regional spread (typically to lymph nodes or adjacent pelvic structures)
- Stage IV: Distant metastases or invasion of bladder/bowel mucosa
Each stage is further subdivided (IA, IB, IC, etc.) to provide more granular prognostic information 1, 2, 3.
Common Staging Pitfalls
If You Meant FIGO Stage IV:
Stage IV represents the most advanced disease category and is managed differently depending on the specific gynecologic malignancy:
For Endometrial Cancer (Stage IVA/IVB):
- Stage IVA: Tumor invades bladder/bowel mucosa
- Stage IVB: Distant metastases including extra-abdominal or inguinal lymph nodes
- Treatment: External beam radiotherapy with concurrent and adjuvant chemotherapy (I, A), or sequential chemotherapy and radiotherapy (I, B) 3
- For MMRd tumors: Consider adjuvant chemotherapy combined with immune checkpoint inhibitor with or without radiotherapy (II, B) 3
For Ovarian Cancer (Stage IV):
- Maximal surgical cytoreduction should be attempted if feasible (III, B) 4
- Platinum-based combination chemotherapy: carboplatin AUC 5-7 plus paclitaxel 175 mg/m² every 3 weeks for six cycles 4
- If surgery not planned, confirm diagnosis by biopsy and proceed with chemotherapy 4
For Cervical Cancer (Stage IVB):
- Palliative chemotherapy after discussion of benefits and risks (B) 5
- Whole body PET or PET-CT scan if salvage therapy being considered (B) 5
- Comprehensive palliative care for declining condition 5
If You Meant a Different Classification:
Some confusion may arise from:
- WHO risk scores (used in gestational trophoblastic disease, which can exceed 7 points) 6, 7, 8
- Appropriateness ratings (1-9 scale used in ACR guidelines, where 5 = "may be appropriate") 9, 2
Critical Action Required
You must clarify which specific gynecologic malignancy and actual stage you are referring to before treatment recommendations can be made. The management of Stage IV disease varies dramatically by:
- Primary tumor site (cervix, endometrium, ovary, etc.)
- Molecular subtype (particularly for endometrial cancer)
- Patient performance status
- Extent of metastatic disease
- Prior treatment history
If you are working with a patient case, review the pathology report and imaging studies to determine the correct FIGO stage (I-IV) and specific substage, then apply the appropriate evidence-based treatment algorithm for that particular malignancy and stage.